Referred to the House Committee on Energy and Commerce.
Amends the Public Health Service Act to reauthorize and adjust a sickle cell disease prevention and treatment demonstration program, broaden wording to include treatment and prevention of complications, authorize grants/contracts/cooperative agreements, increase authorized annual funding to $8,205,000 for FY2025–2029, and includes a Sense of Congress encouraging further research into heritable blood disorders.
Liberals emphasize equity and want larger funding and oversight
Narrow, low-cost, non-ideological reauthorization typically moves easily in the House.
Amends the Public Health Service Act to reauthorize and adjust a sickle cell disease prevention and treatment demonstration program, broaden wording to include treatment and prevention of complications, authorize grants/contracts/cooperative agreements, increase authorized annual funding to $8,205,000 for FY2025–2029, and includes a Sense of Congress encouraging further research into heritable blood disorders.
Content is narrow, bipartisan-friendly, and low-cost; main hurdle is securing appropriations and floor time.
How solid the drafting looks.
Liberals emphasize equity and want larger funding and oversight
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberals emphasize equity and want larger funding and oversight
Generally supportive.
Views the bill as a targeted federal effort to address a racially and geographically concentrated, high-burden disease through research, prevention, and treatment funding.
Would see the funding increase and explicit mention of complications as positive but likely want larger investment and stronger equity provisions.
Cautiously favorable.
Sees a narrowly targeted, bipartisan public-health measure with modest budgetary impact.
Wants clarity on program evaluation, overlap with existing federal efforts, and measurable outcomes before full endorsement.
Skeptical but not uniformly opposed.
Acknowledges value of addressing serious illnesses, but concerned about increased federal spending and broader federal role in health services.
Preference for state-led responses and fiscal offsets.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is narrow, bipartisan-friendly, and low-cost; main hurdle is securing appropriations and floor time.
The bill has not accumulated any surfaced votes yet.
Liberals emphasize equity and want larger funding and oversight
Content is narrow, bipartisan-friendly, and low-cost; main hurdle is securing appropriations and floor time.
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Sickle Cell Disease and Other Heritable Blood Disorders Resear…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.